Publicaciones en colaboración con investigadores/as de Harvard Medical School (7)

2024

  1. Clonal competition assays identify fitness signatures in cancer progression and resistance in multiple myeloma

    HemaSphere, Vol. 8, Núm. 7

2023

  1. Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results

    Nature Medicine, Vol. 29, Núm. 9, pp. 2259-2267

  2. Improving NK cell function in multiple myeloma with NKTR-255, a novel polymer-conjugated human IL-15

    Blood Advances, Vol. 7, Núm. 1, pp. 9-19

2020

  1. Clinical features associated with COVID-19 outcome in multiple myeloma: First results from the International Myeloma Society data set

    Blood, Vol. 136, Núm. 26, pp. 3033-3040

2019

  1. Dual PAK4-NAMPT inhibition impacts growth and survival, and increases sensitivity to DNA-damaging agents in Waldenstrom € macroglobulinemia

    Clinical Cancer Research, Vol. 25, Núm. 1, pp. 369-377

2017

  1. Functional role and therapeutic targeting of p21-activated kinase 4 in multiple myeloma

    Blood, Vol. 129, Núm. 16, pp. 2233-2245

2015

  1. Deep Response in Multiple Myeloma: A Critical Review

    BioMed Research International, Vol. 2015